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ABSTRACT: Probiotics may prevent antibiotic-associated- 
and Clostridium diicile-associated- diarrhoea (AAD/CDAD). 
Many spinal cord injury centres (SCICs) practitioners consider 
probiotics generically and may not realise that eicacy can 
be strain-, dose-, and disease-speciic. One to four SCICs per 
country (depending on population size) were contacted (UK:4; 
the Netherlands:3; Belgium:1; Republic of Ireland:1) to (a) 
determine if they stocked probiotics; (b) determine whether the 
use of those probiotics was evidence-based; and (c) document 
their C. diicile infection (CDI) practices.  All nine SCICs 
responded to the survey (7 physicians, 3 microbiologists, 1 
nurse and 2 dietitians). Five (55.5%) stocked probiotics; 
ive diferent probiotics were identiied. Four probiotics were 
preferred choice prevention of AAD/CDAD were Lactobacillus 
casei Shirota (44.4%), L. casei DN-114001 (22.2%), L. 
acidophilus (22.2%) and a mixed-strains probiotic (Ecologic 
Pro-AD) (11.1%). Only one evidence base study was identiied 
supporting the use of probiotic for prevention of AAD in SCI 
patients. Mean CDI cases per 10,000 patient-days were 0.307 
(s.d: 0.486, range 0.00 to 1.08). Deinitions of diarrhoea 
and CDI varied among SCICs. Stocking probiotics for the 
prevention of AAD/ CDAD is not common. here is only one 
single study showing eiciency of a particular strain in SCI 
populations. he study highlighted the importance of using a 
standardised deinition of diarrhoea when conducting AAD/
CDAD research.
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INTRODUCTION
Probiotics are live organisms that, when administered in 
adequate amounts, confer a health beneit on the host (FAO / 
WHO, 2001). hey are increasingly available as capsules and 
dairy-based food products sold in supermarkets and health 
food shops. Although there are numerous commercially 
available probiotics, there is much debate as to what beneicial 
efects these provide and which speciic organisms may be 
most efective in any speciic patient group. (Hempel et 
al., 2012; Todorov et al., 2011; Ohashi and Ushida, 2009) 
Microorganisms commonly used in probiotic preparations 
include bacteria of the genera Lactobacillus, Biidobacterium, 
Escherichia, Enterococcus or Bacillus,and the fungal genus 
Saccharomyces. (Ohashi and Ushida, 2009)
Diferent probiotic species and strains can have substantially 
diferent efects on the host. (Hickson, 2011; Hill et al., 
2014) Several species- and strain-speciic factors play a role in 
determining what beneits, if any, a probiotic may confer. To 
exert a beneicial efect, a probiotic must irst be able to colonise 
the gastrointestinal (GI) tract. he initial step required for GI 
colonisation by probiotics is adhesion to the GI mucosa. (Van 
and Miller, 2011) Although not fully understood, current 
evidence suggests that the adhesive characteristics of probiotics 
may be due to diferences in the expression of large surface 
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proteins and their interaction with mucus-binding proteins. 
(Van and Miller, 2011) Probiotics have been suggested as a 
mean of preventing adverse GI conditions such as antibiotic-
associated diarrhoea (AAD) and Clostridium diicile-associated 
diarrhoea (CDAD). (Hempel et al., 2012; Todorov et al., 2011; 
Hickson, 2011; Wong et al., 2014) However, this is not a 
characteristic that is shared among all probiotic strains (Ohashi 
and Ushida, 2009; Hickson, 2011; Hill et al., 2014; Van and 
Miller, 2011) and efects may difer with diferent patient 
groups. (Hill et al., 2014; Wong et al., 2014) One example 
where the use of probiotics is particularly likely to be beneicial 
is in patients with spinal cord injury (SCI) who not only require 
an extended period of stay in hospital, but also have increased 
risk of infection due to the use of  urinary catheters for long-term 
bladder management. If diarrhoea develops, rehabilitation will 
be delayed, impacting not just on the patient but also causing 
signiicant extra healthcare costs. Given the severe loss of quality 
of life for SCI patients, if any probiotic is efective, their low 
cost as well as the low incidence of adverse events (Hempel et 
al., 2012) render probiotics an attractive intervention to prevent 
AAD / CDAD.
Probiotics that colonise the GI tract efectively help resist gut 
colonisation by potentially harmful bacteria. Such probiotics 
often have additional properties that beneit the host. (Ohashi 
and Ushida, 2009; Hill et al., 2014) Certain Lactobacillus strains 
can produce antimicrobial compounds, known as bacteriocins, 
which may inhibit pathogens such as Bacillus, Staphylococcus and 
Enterococcus species. A speciic strain of Lactobacillus acidophilus 
produces a bacteriocin that has shown to inhibit strains of Listeria 
innocua and Listeria monocytogenes. (Todorov et al., 2011)
With this in mind, it is important to recognise that there is 
no “generic equivalency” between probiotic species and strains. 
For example, one Lactobacillus casei strain cannot be assumed 
to be equivalent to another Lactobacillus casei strain in terms of 
its efectiveness in a human host. herefore, it is important for 
clinicians to use or recommend speciic commercially available 
probiotics that have speciically been shown to have beneicial 
efects in clinical trials.
Anecdotally, it has been noted that many practitioners 
consider probiotics in generic terms, not recognising that 
there may be diferences between diferent products. Similarly, 
some of the healthcare facilities stock a probiotic, but will not 
substitute one commercial probiotic for another based on cost 
or availability, and without regard for any scientiic evidence to 
support the probiotic in question.
To address this issue, we conducted a survey of specialist 
Spinal Cord Injury Centres (SCICs) in four European countries 
to determine which speciic probiotics were stocked most 
commonly in SCICs. On the basis of the survey results, we then 
conducted a systematic literature review according to expert 
consensus (Hill et al., 2014) to determine whether the probiotics 
that were stocked were supported by any clinical research. 
Our aim was to determine whether SCICs are currently using 
probiotics that are speciically supported by reliable evidence. 
Furthermore, to facilitate future AAD / CDAD research, we 
endeavoured to obtain an understanding of Clostridium diicile 
infection (CDI) management strategies (including diagnostic 
procedures and presence of national surveillance) followed in 
European SCICs. 
MATERIALS AND METHODS
Survey Instrument
A 30 item cross-sectional questionnaire was distributed to 
each SCIC’s lead clinician. he questionnaire consisted of three 
sections: the irst section was aimed at all professional groups 
(medical staf, microbiologist, nursing staf and dietitian); the 
second section was aimed at the SCIC’s medical lead and the 
last section was aimed at the lead microbiologist. In addition 
to gathering demographic data, we enquired about the SCIC’s 
practice (for example, we asked them to provide epidemiological 
data, including numbers of patient-days, admission and use of 
gastric protection). To understand which commercial probiotics 
are stocked in the European SCICs, each SCIC’s lead was asked 
to identify which speciic products they stocked or used in their 
facility, the indications and dose for the probiotic they used, 
their diagnostic criteria for diarrhoea and stool sample testing 
for CDI in October 2014, and technical data such as which 
assays and culture methods were used. Formal ethical permission 
to conduct the study was not required by the Stoke Mandeville 
Hospital review board as this was considered to be a clinical 
audit not involving active patient participation (Health Research 
Authority, 2013); this was accepted by the other centres.  he 
local clinical audit departments approved the questionnaires. In 
addition, we sent the pilot questionnaire to three members of 
our staf to assess the content and time required to complete 
the questionnaire; feedback from this guided the drafting of the 
inal version of the questionnaire. 
 
Survey administration
he survey was administered to SCIC’s medical leads in 
four European countries with a covering letter addressed to 
the local medical lead explaining that our indings would 
be used to identify current CDI practice and to establish if 
SCICs clinicians supported the use of probiotics. We aimed to 
include one SCIC for each country with fewer than 10 million 
inhabitants or fewer, two for countries with between 10 and 
20 million inhabitants, and four for those with more than 20 
million inhabitants, with a balance between academic and 
non-academic institutions. Participants were reassured that 
all indings would be treated anonymously and in conidence 
to encourage respondents to answer honestly. Completed 
questionnaires were anonymised prior to analysis. Two 
reminders were sent (at eight weeks and twelve weeks after the 
initial survey distribution).
Statistical analyses
he incidence rate of healthcare-associated CDI for all SCICs 
was obtained by dividing the number of healthcare-associated 
occurrences by the number of patient-days during the period 
Probiotics and  Diarrhoea   87
covering 1st April 2013 to 31st March 2014. Healthcare-
associated CDI incidence rates were also calculated with the 
total number of admissions as the denominator. Descriptive 
statistics were used to calculate response frequency. Data were 
reported as mean (s.d.) or median (ranges). Generally, statistical 
signiicance was declared for p values less than 0.05. Data were 
analysed with Mintab 15 (Minitab Ltd, Coventry, UK). 
RESULTS
All nine SCICs responded to the survey. he centres contained 
a total of 383 SCI beds (20 in Belgium, 36 in the Republic of 
Ireland, 78 in the Netherlands, and 249 in the United Kingdom.) 
Ten consultants (eight physicians and two microbiologists), one 
nurse (with special interest in infection and prevention control) 
and two dietitians returned the questionnaires.
Of the nine responding SCICS, seven (77.8%) SCICs 
reported using gastric protection to SCI patients when they 
were admitted (Lansprazole (n=3); Omeprazole (n=4); 
Ranitidine (n=5) and others (n=2)). Four (44.4%) SCICs did 
not stock any probiotic products. hree SCICs stocked only 
one probiotic product, and two SCIC stocked more than one 
probiotic product (Fig. 1).   Of the ive SCICs that stocked 
probiotics, the products were used for preventing AAD (n=4); 
TABLE 1. Summary of probiotic use in SCICs in four European countries. Patient days (excluding day-care treatment) during 
1.4.2013 to 31.3.2014; AAD: antibiotic-associated diarrhoea; CDAD: Clostridium diicile associated diarrhoea
Centre 1 Centre 2 Centre 3 Centre 4 Centre 5 Centre 6 Centre 7 Centre 8 Centre 9
No. of SCI beds 48 42 20 25 115 28 44 36 25
No. patients days 15768 13797 7300 8213 35678 9198 14454 13140 7000
Gastric protection to new 
admission
Yes Yes Yes No Yes Yes Yes Yes No
Stocked probiotics
Single strain
Commercial products
No Yes Yes Yes No Yes No Yes No
X X
X X X
Agree probiotic is worthwhile 
to prevent AAD
No Yes Yes Yes Yes No Yes Yes No
Agree probiotic is worthwhile 
to treat AAD
No Yes Yes No Yes No Yes Yes No
Agree probiotic is worthwhile to 
prevent CDAD
No Yes No No Yes No Yes Yes No
Agree probiotic is worthwhile 
to treat CDAD
Yes Yes No No No No Yes Yes No
TABLE 2: Summary of Clostridium diicile management in SCI centres. CDI: Clostridium diicile infection; SCIC: spinal cord 
injury centre; aC. diicile diagnostic criteria: 1: EIA for C. dif toxin A and / or toxin B; 2: EIA for C. dif toxin A only; 3: Cytotoxicity 
test; 4: culture for toxin producing C. di cile; 5: Enzyme for C. diicile- speciic glutamate dehydrogenase; 6: PCR; b1.Cysloserin-
cefoxtin-fructose agar; 2: Cycloserin-cefoxitin-mannitol agar; 3: Brazier medium; 4: Polymerase chain reaction; cFirst line treatment 
of CDI: 1: Vancomycin 125mg 6 hourly PO for 10-14 days; 2: Metronidazole 800mg loading dose then 400mg 8 hourly PO for 
10-14 days; and  dDeinition of diarrhoea: 1: ≥2 watery liquid stools type 5,6 or 7 (Bristol stool scale) over 24 hours; 2: 2: ≥ 2 stools 
per day for ≥3 days; 3: ≥ 3 loose or liquid stools per day; 4 other.
Centre 1  Centre 2 Centre 3 Centre 4 Centre 5 Centre 6 Centre 7 Centre 8 Centre 9
C. diicile policy * Yes Yes * Yes Yes Yes Yes Yes
C. diicile outbreak No No No * No No No No No
Number of CDI in SCIC 0 * 0 * 2 1 1 1 0
CDI cases per 10,000 patient 
days (SCIC)
0 - 0 - 0.56 1.08 0.63 0.76 0
C. diicile diagnostic criteriaa 1 1 1,5,6 1 1 1 1 1 1
Medium for culturing C. 
diicileb
1 1 1 1 3 4 1 4 1
First line treatment of CDI c 1 2 2 2 1 2 1 2 1
Criteria for diarrhoead 1 2 3 2 1 4 1 1 2
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preventing CDAD (n=2) and/or constipation (n=1). (Fig. 2)
Of those SCICs which did not stock probiotic, the reasons 
given were insuicient evidence (n=1), inancial reason (n=1) 
and because probiotic use was not in their centre’s treatment 
policy (n=4) (Table 1).
Five SCICs agreed that a probiotic was worthwhile in 
preventing and/or treating AAD / CDAD, but the length of 
the prescribed probiotic course varied (n=2 (40%) 7 days after 
antibiotic course; n=2 (40%) for the duration of antibiotics 
and; n=1 (20%) dependent on each individual case).  Diferent 
probiotic strains were identiied as potential agents for preventing 
AAD (n =8); and CDAD (n=2). (Fig 3A and Fig 3B).
No SCIC reported any CDI outbreak during the survey 
period. Five SCICs reported they have a CDI policy. Five 
SCICs reported CDI cases and the median CDI cases per 
10,000 days were 0.56 (range: 0-1.08). he methods for 
diagnosing CDI, medium for culturing C. diicile, irst line 
treatment for CDI and diagnostic criteria for diarrhoea varied, 
are summarised in Table 2.
FIGURE 1. Summary of probiotics stocked in SCICs in 
four European countries.
Lactobacillus acidophilus 
n=1; 16.7% 
Saccharomyces boulardii 
n=1; 16.7% 
Lactobacillus casei 
DN‐114001 
n=2;33.2% 
Lactobacillus casei Shirota  
n=1; 16.7% 
Bifdobacterium lac6s 
DN‐173010 
n=1; 16.7% 
FIGURE 2. Summary of condition for which probiotics were 
prescribed. AAD: antibiotic-associated diarrhoea; CDAD: 
Clostridium diicile-associated diarrhoea; 3: constipation
AAD 
57% 
CDAD 
29% 
Cons-pa-on 
14% 
FIGURE 3B.  Summary of the preferred probiotic used by 
the SCICs for Clostridium diicile-associated diarrhoea 
Lactobacillus casei 
DN‐114001 
43% 
Lactobacillus casei 
Shirota 
57% 
Lactobacillus casei 
DN‐114001 
n=2, 15.3% 
Lactobacillus casei Shirota 
n=4; 30.8% 
Lactobacillus acidophilus 
n=2; 15.3% 
Bifdobacteridum biﬁdum 
n=1; 7.7% 
Bifdobacterium infan4s 
n=1; 7.7% 
Lactobacillus rhamnosus 
n=1; 7.7% 
Lactobacillus plantarum 
299v 
n=1; 7.7%  Ecologic Pro 
AD 
n=1; 7.7% 
FIGURE 3A.  Summary of preferred probiotic used by the 
SCICs for antibiotic-associated diarrhoea
Probiotics and  Diarrhoea   89
DISCUSSION
CDI is one of the most problematic gastrointestinal 
infections and one of the main infectious causes of morbidity 
in hospital. Prevention of CDI relies on methods to reduce 
transmission of the pathogen through efective hand hygiene, 
barrier precautions, isolation of patients, adequate nutrition 
and hydration and environment cleaning. (Public Health 
England., 2013) Perhaps even more important are attempts to 
reduce host susceptibility to infection by reducing unnecessary 
antibiotic use. (Kelly and LaMont, 2008) Antibiotic use 
disrupts and depletes the normal gastrointestinal lora, 
allowing C. diicile to thrive and generate clinical disease. 
(Kelly and LaMont, 2008) When antibiotic treatment is 
unavoidable, reinforcement of the colonic microbiota could 
be another means to decrease susceptibility of patients to CDI. 
Deinitive restoration of the colonic ecosystem through faecal 
microbiota transplantation has potential important impact in 
the treatment of established CDI and prevention of recurrence. 
(Van Nood et al., 2013) A more palatable approach to boost 
colonic defences is the use of non-pathogenic microbial 
supplements, known as probiotics. Probiotics have been 
shown to elicit various biological efects through their ability 
to colonise the GI tract, produce antimicrobial compounds, 
and other strain-speciic actions such as immune modulations. 
Because these efects are speciic for each probiotic strain 
or combinations of strains, any beneits reported in clinical 
studies are not generalisable to other probiotics, even within 
the same microbial species. (Hickson, 2011; Hill et al., 2014) 
herefore, a reliable evidence base speciic to that probiotic 
product should support use of any probiotic in SCIC.
he nine SCICs responding to the survey reported use of 
ive diferent probiotic strains in their centres.  In an attempt 
to locate evidence speciically to SCI patients, we preformed a 
systematic literature search restricted our search to randomised 
controlled trials that assessed probiotic in SCI patients exposed 
to antibiotics. We searched Cochrane Central Register of 
Controlled Trials, Health Technology Assessment Database; 
CINAHL; PsycINFO; EMBASE; Medline; AMED and 
DARE from date of inception to Feb 2015 used the following 
terms (with synonyms and closely related words): “spinal cord 
injuries” combined with  “antibiotic-associated diarrhoea” 
and “probiotic”. (Wong et al., 2015)  Our search identiied 
only one study reporting evidence of probiotic beneit 
against AAD in an SCI population, which was one of those 
probiotics: Lactobacillus casei Shirota. (Wong et al., 2014)  Our 
review did not ind any studies conducted in SCI populations 
that investigated use of probiotics for preventing or treating 
CDAD and constipation in the SCI population, although 
there are several studies with the general population (Hempel 
et al., 2013; McFarland, 2007).  Overall, no probiotic was 
supported by a strong evidence base, mainly due to the lack of 
consistent beneit from diferent studies. L. casei Shirota and 
L. Casei DN-14001 appear to be the choice of probiotic for 
prevention of AAD / CDAD. Only 25% and 50% of SCICs 
stocked L. casei Shirota and L. Casei DN-14001, respectively, 
whereas 50% of SCICs stocked at least one probiotic that 
was supported by low or no evidence. hese results suggested 
that a majority of SCICs stock a probiotic that lacks reliable 
evidence. Although we only found only one study reported the 
eicacy of probiotic in preventing AAD in SCI patients, the 
other probiotic strains may also be efective. Further studies 
are warranted to evaluate the use of a speciic probiotic strain 
in SCI populations.
Barbut and colleagues reported a mean incidence of CDI 
in 23 European hospitals of 2.45 per 10,000 patient-days 
(range: 0.1 to 7.1), (Barbut et al., 2007) which is higher 
than the igure of 0.56 per 10,000 patient-days in our study 
thus the CDI incidence rates of participating SCIC were not 
representative of national incidence rates. he low incidence of 
CDI could be due to the continuing year-on-year fall of overall 
CDI cases. Indeed, the overall CDI rate for England has fallen 
from 4.85 per 10,000 in 2009 to 2.29 per 10,000 in 2013. 
(Public Health England, 2014) 
he present study found that the incidence of CDI, choice 
of CDI treatment and deinition of diarrhoea vary greatly 
between SCICs. At this present time, no consensus exists 
on optimal testing for CDI since uniform diagnostic (and 
culture) methods do not exist. To involve the international 
microbiology association in setting standards would not just 
help in identifying and treating patients with SCI but also for 
future AAD / CDAD research. 
his study has some limitations. Firstly, the selection of 
the SCICs in each country was at discretion of the principal 
investigator and the number of SCICs per country was small. 
However, the SCICs selected represented approximately 40% 
of the SCICs in the Belgium, UK and the Netherland, and 
100% in the Republic of Ireland.  herefore, results derived 
from this sample of SCICs could be considered representative 
of each country. Secondly, there may have been diferences 
in physicians’ awareness of infection and probiotics between 
SCICs and countries.
CONCLUSIONS
Stocking probiotics for the prevention of AAD/ CDAD is 
not common. here is only one single study showing eiciency 
of a particular strain in SCI populations. SCICs should review 
the supporting evidence for each probiotic prior to stocking. 
Further research of speciic probiotic strains is needed to 
provide more data that SCIC can use to make informed 
formulary and purchasing decisions. he data also emphasised 
the importance of using a standardised deinition of diarrhoea 
when conducting future AAD / CDAD research.
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